Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia

Takefumi Suzuki, Gary Remington, Tamara Arenovich, Hiroyuki Uchida, Ofer Agid, Ariel Graff-Guerrero, David C. Mamo

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Improvements are greatest in the earlier weeks of antipsychotic treatment of patients with non-resistant schizophrenia. Aims: To address the early time-line for improvement with antipsychotics in treatment-resistant schizophrenia. Method: Randomised double-blind trials of antipsychotic medication in adult patients with treatment-resistant schizophrenia were investigated (last search June 2010). A series of metaregression analyses were carried out to examine the effect of time on the average item scores in the Positive and Negative Syndrome Scale (PANSS) or Brief Psychiatric Rating Scale (BPRS) at three or more distinct time points within the first 6 weeks of treatment. Results: Study duration varied from 4 weeks to 1 year and the definitions of treatment resistance as well as of treatment response were not necessarily consistent across 19 identified studies, resulting in highly variable rates of response (0-76%). The mean standardised baseline item score in the PANSS or BPRS was 3.4 (s.e. = 0.06) in the five studies included in the meta-regression analysis, with the average baseline Clinical Global Impression - Severity score being 5.2 (marked illness). For the pooled population treated with a range of antipsychotics (n = 1019), significant reductions in the mean item scores occurred during the first 4 weeks; improvements observed in later weeks were smaller and non-significant. In contrast, weekly improvement with clozapine was significant throughout (n = 356). Conclusions: Our findings provide preliminary evidence that the majority of improvement with antipsychotics may occur relatively early. More consistent improvements with clozapine may be associated with a gradual titration. To further elucidate response patterns, future studies are needed to provide data over regular intervals during earlier stages of treatment.

Original languageEnglish
Pages (from-to)275-280
Number of pages6
JournalBritish Journal of Psychiatry
Volume199
Issue number4
DOIs
Publication statusPublished - 2011 Oct

Fingerprint

Antipsychotic Agents
Schizophrenia
Brief Psychiatric Rating Scale
Clozapine
Therapeutics
Double-Blind Method
Meta-Analysis
Regression Analysis
Population

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. / Suzuki, Takefumi; Remington, Gary; Arenovich, Tamara; Uchida, Hiroyuki; Agid, Ofer; Graff-Guerrero, Ariel; Mamo, David C.

In: British Journal of Psychiatry, Vol. 199, No. 4, 10.2011, p. 275-280.

Research output: Contribution to journalArticle

Suzuki, T, Remington, G, Arenovich, T, Uchida, H, Agid, O, Graff-Guerrero, A & Mamo, DC 2011, 'Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia', British Journal of Psychiatry, vol. 199, no. 4, pp. 275-280. https://doi.org/10.1192/bjp.bp.110.083907
Suzuki, Takefumi ; Remington, Gary ; Arenovich, Tamara ; Uchida, Hiroyuki ; Agid, Ofer ; Graff-Guerrero, Ariel ; Mamo, David C. / Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. In: British Journal of Psychiatry. 2011 ; Vol. 199, No. 4. pp. 275-280.
@article{866bf80369094a32b49e6ebe41dfa3cb,
title = "Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia",
abstract = "Background: Improvements are greatest in the earlier weeks of antipsychotic treatment of patients with non-resistant schizophrenia. Aims: To address the early time-line for improvement with antipsychotics in treatment-resistant schizophrenia. Method: Randomised double-blind trials of antipsychotic medication in adult patients with treatment-resistant schizophrenia were investigated (last search June 2010). A series of metaregression analyses were carried out to examine the effect of time on the average item scores in the Positive and Negative Syndrome Scale (PANSS) or Brief Psychiatric Rating Scale (BPRS) at three or more distinct time points within the first 6 weeks of treatment. Results: Study duration varied from 4 weeks to 1 year and the definitions of treatment resistance as well as of treatment response were not necessarily consistent across 19 identified studies, resulting in highly variable rates of response (0-76{\%}). The mean standardised baseline item score in the PANSS or BPRS was 3.4 (s.e. = 0.06) in the five studies included in the meta-regression analysis, with the average baseline Clinical Global Impression - Severity score being 5.2 (marked illness). For the pooled population treated with a range of antipsychotics (n = 1019), significant reductions in the mean item scores occurred during the first 4 weeks; improvements observed in later weeks were smaller and non-significant. In contrast, weekly improvement with clozapine was significant throughout (n = 356). Conclusions: Our findings provide preliminary evidence that the majority of improvement with antipsychotics may occur relatively early. More consistent improvements with clozapine may be associated with a gradual titration. To further elucidate response patterns, future studies are needed to provide data over regular intervals during earlier stages of treatment.",
author = "Takefumi Suzuki and Gary Remington and Tamara Arenovich and Hiroyuki Uchida and Ofer Agid and Ariel Graff-Guerrero and Mamo, {David C.}",
year = "2011",
month = "10",
doi = "10.1192/bjp.bp.110.083907",
language = "English",
volume = "199",
pages = "275--280",
journal = "British Journal of Psychiatry",
issn = "0007-1250",
publisher = "Royal College of Psychiatrists",
number = "4",

}

TY - JOUR

T1 - Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia

AU - Suzuki, Takefumi

AU - Remington, Gary

AU - Arenovich, Tamara

AU - Uchida, Hiroyuki

AU - Agid, Ofer

AU - Graff-Guerrero, Ariel

AU - Mamo, David C.

PY - 2011/10

Y1 - 2011/10

N2 - Background: Improvements are greatest in the earlier weeks of antipsychotic treatment of patients with non-resistant schizophrenia. Aims: To address the early time-line for improvement with antipsychotics in treatment-resistant schizophrenia. Method: Randomised double-blind trials of antipsychotic medication in adult patients with treatment-resistant schizophrenia were investigated (last search June 2010). A series of metaregression analyses were carried out to examine the effect of time on the average item scores in the Positive and Negative Syndrome Scale (PANSS) or Brief Psychiatric Rating Scale (BPRS) at three or more distinct time points within the first 6 weeks of treatment. Results: Study duration varied from 4 weeks to 1 year and the definitions of treatment resistance as well as of treatment response were not necessarily consistent across 19 identified studies, resulting in highly variable rates of response (0-76%). The mean standardised baseline item score in the PANSS or BPRS was 3.4 (s.e. = 0.06) in the five studies included in the meta-regression analysis, with the average baseline Clinical Global Impression - Severity score being 5.2 (marked illness). For the pooled population treated with a range of antipsychotics (n = 1019), significant reductions in the mean item scores occurred during the first 4 weeks; improvements observed in later weeks were smaller and non-significant. In contrast, weekly improvement with clozapine was significant throughout (n = 356). Conclusions: Our findings provide preliminary evidence that the majority of improvement with antipsychotics may occur relatively early. More consistent improvements with clozapine may be associated with a gradual titration. To further elucidate response patterns, future studies are needed to provide data over regular intervals during earlier stages of treatment.

AB - Background: Improvements are greatest in the earlier weeks of antipsychotic treatment of patients with non-resistant schizophrenia. Aims: To address the early time-line for improvement with antipsychotics in treatment-resistant schizophrenia. Method: Randomised double-blind trials of antipsychotic medication in adult patients with treatment-resistant schizophrenia were investigated (last search June 2010). A series of metaregression analyses were carried out to examine the effect of time on the average item scores in the Positive and Negative Syndrome Scale (PANSS) or Brief Psychiatric Rating Scale (BPRS) at three or more distinct time points within the first 6 weeks of treatment. Results: Study duration varied from 4 weeks to 1 year and the definitions of treatment resistance as well as of treatment response were not necessarily consistent across 19 identified studies, resulting in highly variable rates of response (0-76%). The mean standardised baseline item score in the PANSS or BPRS was 3.4 (s.e. = 0.06) in the five studies included in the meta-regression analysis, with the average baseline Clinical Global Impression - Severity score being 5.2 (marked illness). For the pooled population treated with a range of antipsychotics (n = 1019), significant reductions in the mean item scores occurred during the first 4 weeks; improvements observed in later weeks were smaller and non-significant. In contrast, weekly improvement with clozapine was significant throughout (n = 356). Conclusions: Our findings provide preliminary evidence that the majority of improvement with antipsychotics may occur relatively early. More consistent improvements with clozapine may be associated with a gradual titration. To further elucidate response patterns, future studies are needed to provide data over regular intervals during earlier stages of treatment.

UR - http://www.scopus.com/inward/record.url?scp=80053432987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053432987&partnerID=8YFLogxK

U2 - 10.1192/bjp.bp.110.083907

DO - 10.1192/bjp.bp.110.083907

M3 - Article

VL - 199

SP - 275

EP - 280

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

SN - 0007-1250

IS - 4

ER -